{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:53:24Z","timestamp":1786978404324,"version":"build-2736575974"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":1715,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Down syndrome (DS) is a genetic disorder caused by trisomy 21 (T21). Over the past two decades, the use of mouse models has led to significant advances in the understanding of mechanisms underlying various phenotypic features and comorbidities secondary to T21 and even informed the design of clinical trials aimed at enhancing the cognitive abilities of persons with DS. In spite of its success, this approach has been plagued by all the typical limitations of rodent modeling of human disorders and diseases. Recently, several laboratories have succeeded in producing T21 human induced pluripotent stem cells (T21-iPSCs) from individuals with DS, which is emerging as a promising complementary tool for the study of DS. Here, we describe the method by which we generated 10 T21-iPSC lines from epithelial cells in urine samples, presumably from kidney epithelial origin, using nonintegrating episomal vectors. We also show that these iPSCs maintain chromosomal stability for well over 20 passages and are more sensitive to proteotoxic stress than euploid iPSCs. Furthermore, these iPSC lines can be differentiated into glutamatergic neurons and cardiomyocytes. By culturing urine-derived cells and maximizing the efficiency of episomal vector transfection, we have been able to generate iPSCs noninvasively and effectively from participants with DS in an ongoing clinical trial, and thus address most shortcomings of previously generated T21-iPSC lines. These techniques should extend the application of iPSCs in modeling DS and other neurodevelopmental and neurodegenerative disorders, and may lead to future human cell-based platforms for high-throughput drug screening.<\/jats:p>","DOI":"10.1002\/sctm.16-0128","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T12:55:45Z","timestamp":1490705745000},"page":"1465-1476","source":"Crossref","is-referenced-by-count":36,"title":["Generation of Integration-Free Induced Pluripotent Stem Cells from Urine-Derived Cells Isolated from Individuals with Down Syndrome"],"prefix":"10.1093","volume":"6","author":[{"given":"Young","family":"M. Lee","sequence":"first","affiliation":[{"name":"a Division of Pediatric Neurology, Department of Pediatrics, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna L.","family":"Zampieri","sequence":"additional","affiliation":[{"name":"a Division of Pediatric Neurology, Department of Pediatrics, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah J.","family":"Scott-McKean","sequence":"additional","affiliation":[{"name":"a Division of Pediatric Neurology, Department of Pediatrics, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Johnson","sequence":"additional","affiliation":[{"name":"a Division of Pediatric Neurology, Department of Pediatrics, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto C.S.","family":"Costa","sequence":"additional","affiliation":[{"name":"a Division of Pediatric Neurology, Department of Pediatrics, Cleveland, Ohio, USA"},{"name":"b Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"key":"2022022809335301700_R1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/bdra.20735","article-title":"Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth","volume":"88","author":"Parker","year":"2010","journal-title":"Defects Res A Clin Mol Teratol"},{"key":"2022022809335301700_R2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0006-8993(83)91179-4","article-title":"Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome","volume":"280","author":"Yates","year":"1983","journal-title":"Brain Res"},{"key":"2022022809335301700_R3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1034\/j.1601-183X.2003.00026.x","article-title":"Down's syndrome: A genetic disorder in biobehavioral perspective","volume":"2","author":"Nadel","year":"2003","journal-title":"Genes Brain Behav"},{"key":"2022022809335301700_R4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrg1525","article-title":"Down syndrome and genetics - a case of linked histories","volume":"6","author":"Patterson","year":"2005","journal-title":"Nat Rev Genet"},{"key":"2022022809335301700_R5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00431-010-1200-0","article-title":"Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome","volume":"169","author":"Weijerman","year":"2010","journal-title":"Eur J Pediatr"},{"key":"2022022809335301700_R6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2249.2011.04335.x","article-title":"Infections and immunodeficiency in Down syndrome","volume":"164","author":"Ram","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"2022022809335301700_R7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40263-013-0089-3","article-title":"Prospects for improving brain function in individuals with Down syndrome","volume":"27","author":"Costa","year":"2013","journal-title":"CNS Drugs"},{"key":"2022022809335301700_R8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"2022022809335301700_R9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/jcm4040696","article-title":"Concise review: Methods and cell types used to generate down syndrome induced pluripotent stem cells","volume":"4","author":"Hibaoui","year":"2015","journal-title":"J Clin Med"},{"key":"2022022809335301700_R10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.yexcr.2012.09.017","article-title":"Modeling neurogenesis impairment in Down syndrome with induced pluripotent stem cells from Trisomy 21 amniotic fluid cells","volume":"319","author":"Lu","year":"2013","journal-title":"Exp Cell Res"},{"key":"2022022809335301700_R11","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1681\/ASN.2011010106","article-title":"Generation of induced pluripotent stem cells from urine","volume":"22","author":"Zhou","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2022022809335301700_R12","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/nprot.2012.115","article-title":"Generation of human induced pluripotent stem cells from urine samples","volume":"7","author":"Zhou","year":"2012","journal-title":"Nat Protoc"},{"key":"2022022809335301700_R13","first-page":"52032","article-title":"Generation of induced pluripotent stem cells from muscular dystrophy patients: Efficient integration-free reprogramming of urine derived cells","volume":"28","author":"Afzal","year":"2015","journal-title":"J Vis Exp"},{"key":"2022022809335301700_R14","first-page":"101","article-title":"Generation of induced pluripotent stem cells from renal tubular cells of a patient with Alport syndrome","volume":"8","author":"Chen","year":"2015","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2022022809335301700_R15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1242\/dmm.022277","article-title":"Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia","volume":"9","author":"Si-Tayeb","year":"2016","journal-title":"Dis Model Mech"},{"key":"2022022809335301700_R16","doi-asserted-by":"crossref","first-page":"2452985","DOI":"10.1155\/2016\/2452985","article-title":"Modeling neurological disease by rapid conversion of human urine cells into functional neurons","volume":"2016","author":"Zhang","year":"2016","journal-title":"Stem Cells Int"},{"key":"2022022809335301700_R17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5966\/sctm.2012-0117","article-title":"Concise review: New paradigms for Down syndrome research using induced pluripotent stem cells: Tackling complex human genetic disease","volume":"2","author":"Briggs","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"2022022809335301700_R18","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/stem.201","article-title":"Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells","volume":"27","author":"Zhou","year":"2009","journal-title":"Stem Cells"},{"key":"2022022809335301700_R19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1172482","article-title":"Human induced pluripotent stem cells free of vector and transgene sequences","volume":"324","author":"Yu","year":"2009","journal-title":"Science"},{"key":"2022022809335301700_R20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/stem.1297","article-title":"Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology","volume":"31","author":"Briggs","year":"2013","journal-title":"Stem Cells"},{"key":"2022022809335301700_R21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.stem.2011.03.002","article-title":"A call for standardized naming and reporting of human ESC and iPSC lines","volume":"8","author":"Luong","year":"2011","journal-title":"Cell Stem Cell"},{"key":"2022022809335301700_R22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ymeth.2008.03.005","article-title":"Protocols for cytogenetic studies of human embryonic stem cells","volume":"45","author":"Meisner","year":"2008","journal-title":"Methods"},{"key":"2022022809335301700_R23","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1038\/nprot.2006.358","article-title":"Spectral karyotyping analysis of human and mouse chromosomes","volume":"1","author":"Padilla-Nash","year":"2006","journal-title":"Nat Protoc"},{"key":"2022022809335301700_R24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.nbd.2013.09.005","article-title":"Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: A model system to study neurotoxicity in Alzheimer's disease","volume":"62","author":"Vazin","year":"2014","journal-title":"Neurobiol Dis"},{"key":"2022022809335301700_R25","first-page":"52010","article-title":"High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry","volume":"25","author":"Bhattacharya","year":"2014","journal-title":"J Vis Exp"},{"key":"2022022809335301700_R26","doi-asserted-by":"crossref","first-page":"17567","DOI":"10.1073\/pnas.1215468109","article-title":"Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells","volume":"109","author":"Maclean","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022022809335301700_R27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nbt922","article-title":"Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells","volume":"22","author":"Draper","year":"2004","journal-title":"Nat Biotechnol"},{"key":"2022022809335301700_R28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nbt0105-19","article-title":"Preserving the genetic integrity of human embryonic stem cells","volume":"23","author":"Mitalipova","year":"2005","journal-title":"Nat Biotechnol"},{"key":"2022022809335301700_R29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1600-0463.2005.apm_305.x","article-title":"Human embryonic stem cells and chromosome stability","volume":"113","author":"Hanson","year":"2005","journal-title":"APMIS"},{"key":"2022022809335301700_R30","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/stem.1961","article-title":"Perturbations of heart development and function in cardiomyocytes from human embryonic stem cells with trisomy 21","volume":"33","author":"Bosman","year":"2015","journal-title":"Stem Cells"},{"key":"2022022809335301700_R31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cell.2011.01.017","article-title":"Identification of aneuploidy-selective antiproliferation compounds","volume":"144","author":"Tang","year":"2011","journal-title":"Cell"},{"key":"2022022809335301700_R32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.stem.2012.06.007","article-title":"mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis","volume":"11","author":"Iglesias-Bartolome","year":"2012","journal-title":"Cell Stem Cell"},{"key":"2022022809335301700_R33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1083\/jcb.201009094","article-title":"Four faces of cellular senescence","volume":"192","author":"Rodier","year":"2011","journal-title":"J Cell Biol"},{"key":"2022022809335301700_R34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.prp.2012.03.010","article-title":"Detection of novel genomic aberrations in anaplastic astrocytomas by GTG-banding, SKY, locus-specific FISH, and high density SNP-array","volume":"208","author":"Holland","year":"2012","journal-title":"Pathol Res Pract"},{"key":"2022022809335301700_R35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.stem.2012.08.004","article-title":"Trisomy correction in Down syndrome induced pluripotent stem cells","volume":"11","author":"Li","year":"2012","journal-title":"Cell Stem Cell"},{"key":"2022022809335301700_R36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/dnares\/dsv016","article-title":"Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures","volume":"22","author":"Amano","year":"2015","journal-title":"DNA Res"},{"key":"2022022809335301700_R37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nature12394","article-title":"Translating dosage compensation to trisomy 21","volume":"500","author":"Jiang","year":"2013","journal-title":"Nature"},{"key":"2022022809335301700_R38","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1523\/JNEUROSCI.5338-13.2014","article-title":"Glutamatergic transmission aberration: A major cause of behavioral deficits in a murine model of Down's syndrome","volume":"34","author":"Kaur","year":"2014","journal-title":"J Neurosci"},{"key":"2022022809335301700_R39","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1038\/tp.2012.66","article-title":"Antagonism of NMDA receptors as a potential treatment for Down syndrome: A pilot randomized controlled trial","volume":"2","author":"Boada","year":"2012","journal-title":"Transl Psychiatry"},{"key":"2022022809335301700_R40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/18715273113126660183","article-title":"The glutamatergic hypothesis for Down syndrome: The potential use of N-methyl-D-aspartate receptor antagonists to enhance cognition and decelerate neurodegeneration","volume":"13","author":"Costa","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2022022809335301700_R41","first-page":"44","article-title":"Study of Down syndrome in 238,942 consecutive births","volume":"41","author":"Stoll","year":"1998","journal-title":"Ann Genet"},{"key":"2022022809335301700_R42","first-page":"894","article-title":"[Heart malformations in children with Down syndrome]","volume":"56","author":"Rubens Figueroa","year":"2003","journal-title":"Rev Esp Cardiol"},{"key":"2022022809335301700_R43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2147\/TCRM.S10235","article-title":"Reduced exercise capacity in persons with Down syndrome: Cause, effect, and management","volume":"6","author":"Mendonca","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"2022022809335301700_R44","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1053\/S0003-9993(03)00342-3","article-title":"Chronotropic incompetence in persons with down syndrome","volume":"84","author":"Guerra","year":"2003","journal-title":"Arch Phys Med Rehabil"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsctm.16-0128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/6\/6\/1465\/42630797\/stcltm_6_6_1465.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/6\/6\/1465\/42630797\/stcltm_6_6_1465.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T05:02:48Z","timestamp":1719118968000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/6\/6\/1465\/6398814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,3,28]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/sctm.16-0128","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6,1]]},"published":{"date-parts":[[2017,3,28]]}}}